European Commission seeks biopharma feedback on Novo-Catalent deal — reportnews2024-11-14T17:55:02+00:00November 14th, 2024|Endpoints News|
Lonza expands bioconjugates factory; WuXi Bio adds capacity in Germany news2024-11-14T16:23:41+00:00November 14th, 2024|Endpoints News|
New Zealand clears first clinical trial of epigenetic editing for hepatitis Bnews2024-11-14T16:12:43+00:00November 14th, 2024|Endpoints News|
Novo Nordisk to phase out its production of human insulin pens globallynews2024-11-14T16:09:23+00:00November 14th, 2024|Endpoints News|
Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ optionsnews2024-11-14T15:56:45+00:00November 14th, 2024|Endpoints News|
As bluebird projects more commercial demand, the biotech continues to seek cashnews2024-11-14T15:11:21+00:00November 14th, 2024|Endpoints News|
BeiGene rebrands as BeOne Medicines, dropping name’s link to Chinanews2024-11-14T15:05:14+00:00November 14th, 2024|Endpoints News|
Merck KGaA’s life science unit is still feeling the Covid demand declinenews2024-11-14T14:29:08+00:00November 14th, 2024|Endpoints News|
Merck buys into PD-1/VEGF space as Summit comes for Keytrudanews2024-11-14T12:29:52+00:00November 14th, 2024|Endpoints News|
Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpactnews2024-11-14T12:00:06+00:00November 14th, 2024|Endpoints News|
